CardioLogical Solutions receives an additional patent for its aortic embolic protection devices designed to prevent stroke and other ischaemic complications

268

CardioLogical Solutions has announced that it has been issued an additional patent for its family of aortic embolic protection devices that are designed to prevent stroke and other ischemic complications

According to a company press release, the aortic embolic protection technologies of Emboline and the large-hole access and closure technologies of VasoStitch form the initial core of a suite of accessory devices offered by CardioLogical Solutions to address the clinical needs of emerging interventional cardiology procedures. The press release also stated that added to these accessory devices, is a novel approach to preventing contrast nephropathy during cardiovascular procedures. The technologies of CardioLogical Solutions are derived from intellectual property invented by serial entrepreneur Amir Belson, founder of NeoGuide Systems, Vascular Pathways, Zipline Medical, Thermocure and Radguard Medical.


“This new issued patent affords CardioLogical Solutions additional IP protection for the most comprehensive range of accessory products aimed at the TAVR community today,” said David WJ Smith, CEO. “Indeed, our three platforms of procedural accessory devices address the three most pressing clinical needs in the rapidly growing evolution of transcatheter aortic valve replacement (TAVR) therapies: specifically, (1) a dire need for nonsurgical, large-hole (>12 Fr) access and closure technologies, (2) aortic embolic protection devices for prevention of stroke and other ischemic complications, and (3) prevention of contrast nephropathy. The combined potential of these markets where there exists now a strong clinical need is estimated at $2 to $3 billion per year, and this is where CardioLogical Solutions is focused.”

 


CardioLogical Solutions is currently in the advanced stages of raising a Series B preferred round to achieve CE mark for the initial Emboline and VasoStitch products, and proof-of-concept for its contrast nephropathy technology. First commercial sales are estimated in the ninth calendar quarter following close of funding, beginning with the European launch of the first VasoStitch product, followed by the European launch of the first Emboline device approximately six months later.

 
CardioLogical Solutions’ products are not available for sale in the United States.